Goodconazole 200 Capsule contains Itraconazole 200 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various fungal infections, including dermatophytosis, onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and candidiasis affecting the skin, nails, and systemic sites. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. Disruption of ergosterol synthesis leads to increased membrane permeability and ultimately fungal cell death. Goodconazole 200 Capsule is typically administered orally, with dosage and duration tailored to the type and severity of infection, as well as patient-specific factors such as age, hepatic function, and concomitant medications. It is important to monitor liver function during prolonged therapy due to potential hepatotoxicity. Caution is advised when co-administering with drugs metabolized by CYP3A4, as itraconazole is a potent inhibitor of this enzyme, potentially leading to significant drug interactions. Patients should be advised to complete the full course of therapy to prevent recurrence and resistance. Goodconazole 200 Capsule offers an effective therapeutic option for managing resistant and systemic fungal infections under appropriate medical supervision.